MedTrace Logo

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

NCT05010005 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-04-09

No results posted yet for this study

Summary

This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.

This study has three parts: dose escalation (Part 1), dose expansion (Part 2), and TFH/T-PLL cohort expansion (Part 3).

Conditions

  • T-cell Lymphomas
  • NK-Cell Lymphomas
  • T-cell Prolymphocytic Leukemia
  • T-cell Large Granular Lymphocyte Leukemia

Interventions

DRUG

Ruxolitinib

Ruxolitinib 20mg BID

DRUG

Duvelisib

Duvelisib 25mg, 50mg, or 75mg BID

Sponsors & Collaborators

Principal Investigators

  • Alison Moskowitz, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-12
Primary Completion
2027-08-31
Completion
2027-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05010005 on ClinicalTrials.gov